The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells

Endocrine-Related Cancer

Volumn 18, Issue 2, 2011, Pages 277-285

  Zitzmann, Kathrin ^a   De Toni, Enrico ^a   Von Rüden, Janina ^a   Brand, Stephan ^a   Göke, Burkhard ^a   Laubender, Rüdiger P ^b   Auernhammer, Christoph J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CHIR 265; EVEROLIMUS; FLICE INHIBITORY PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NVP AEW 541; PROTEIN BCL 2; RAF PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; BRONCHUS CARCINOID; DRUG INHIBITION; HUMAN; HUMAN CELL; INSULINOMA; NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; NEUROENDOCRINE TUMORS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; QUINOLINES; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIROLIMUS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOR SERINE-THREONINE KINASES;

EID: 79953201876     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0108     Document Type: Article

References (27)

1. Balmanno K & Cook SJ 2009 Tumour cell survival signalling by the ERK1/2 pathway. Cell Death and Differentiation 16 368-377. (doi:10.1038/cdd. 2008.148)
2. Boisvert-Adamo K & Aplin AE 2008 Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 27 3301-3312. (doi:10.1038/sj.onc.1211003)
3. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J & Rivard N 2000 MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. Journal of Cellular Biochemistry 79 355-369. (doi:10. 1002/1097-4644(20001201)79:3〈355::AID- JCB20〉3.0.CO;2-0)
4. Elias A, Siegelin MD, Steinmuller A, von Deimling A, Lass U, Korn B & Mueller W 2009 Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clinical Cancer Research 15 5457-5465. (doi:10.1158/1078-0432.CCR-09-1125)
5. Griffith TS, Stokes B, Kucaba TA, Earel JK Jr, VanOosten RL, Brincks EL & Norian LA 2009 TRAIL gene therapy: from preclinical development to clinical application. Current Gene Therapy 9 9-19. (doi:10.2174/ 156652309787354612)
6. Höpfner M, Baradari V, Huether A, Schöfl C & Scherübl H 2006 The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocrine-Related Cancer 13 135-149. (doi:10.1677/erc.1.01090)
7. Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C & Krainer M 2005 Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Molecular Cancer Research 3 335-343. (doi:10.1158/1541-7786.MCR-04-0136)
8. Mahalingam D, Szegezdi E, Keane M, Jong S & Samali A 2009 TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treatment Reviews 35 280-288. (doi:10.1016/j.ctrv.2008.11.006)
9. Majewski N, Nogueira V, Robey RB & Hay N 2004 Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Molecular and Cellular Biology 24 730-740. (doi:10.1128/MCB.24.2.730-740.2004)
10. Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD et al. 2007 Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. Journal of Biological Chemistry 282 29831-29846. (doi:10.1074/jbc.M706110200)
11. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F & Riccardi C 1991 A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Journal of Immunological Methods 139 271-279. (doi:10.1016/0022-1759(91)90198-O)
12. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM & Fulda S 2008 Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Research 68 6271-6280. (doi:10.1158/0008-5472.CAN-07-6769)
13. Panner A, James CD, Berger MS & Pieper RO 2005 mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Molecular and Cellular Biology 25 8809-8823. (doi:10.1128/MCB.25.20.8809-8823.2005)
14. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ et al. 2007 Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12 66-80. (doi:10.1016/j.ccr.2007.05.006)
15. Rosato RR, Almenara JA, Coe S & Grant S 2007 The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Research 67 9490-9500. (doi:10.1158/0008-5472.CAN-07-0598)
16. Shivapurkar N, Reddy J, Matta H, Sathyanarayana UG, Huang CX, Toyooka S, Minna JD, Chaudhary PM & Gazdar AF 2002 Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21 8510-8514. (doi:10.1038/sj.onc.1205941)
17. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR & Yagita H 2003 Nature's TRAIL - on a path to cancer immunotherapy. Immunity 18 1-6. (doi:10.1016/S1074-7613(02)00502-2)
18. Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L et al. 2008 Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Research 68 9394-9403. (doi:10.1158/0008-5472.CAN-08-2815)
19. Uchida M, Iwase M, Takaoka S, Yoshiba S, Kondo G, Watanabe H, Ohashi M, Nagumo M & Shintani S 2007 Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors. International Journal of Oncology 30 1163-1171.
20. Walczak H, Koschny R, Willen D, Schader MB, Sykora J, Ganten TM & Haas TL 2008 The TRAIL receptor-ligand system: biochemistry of apoptosis induction, therapeutic potential for cancer treatment and physiological function. In Apoptosis and Cancer Therapy, pp 31-92. Ed PDDSF Prof. Dr Klaus-Michael Debatin.
21. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G & Seufferlein T 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research 60 4573-4581. (Pubitemid 32103642)
22. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al. 1995 Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 673-682. (doi:10.1016/1074-7613(95)90057-8)
23. Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D & DiPietro R 2005 PI-3K/Akt and NF-kappaB/IkappaB-alpha pathways are activated in Jurkat T cells in response to TRAIL treatment. Journal of Cell Physiology 202 900-911. (doi:10.1002/jcp.20202)
24. Zhang L & Fang B 2005 Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Therapy 12 228-237. (doi:10.1038/sj.cgt. 7700792)
25. Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, Spottl G, Meyer H & Auernhammer CJ 2006 Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochemical and Biophysical Research Communications 344 1334-1341. (doi:10.1016/j.bbrc.2006.04.043)
26. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH & Auernhammer CJ 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85 54-60. (doi:10.1159/000100057)
27. Zitzmann K, Ruden JV, Brand S, Goke B, Lichtl J, Spottl G & Auernhammer CJ 2010 Compensatory activation of Akt in response to mTOR and Raf inhibitors - A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Letters 295 100-109. (doi:10.1016/j.canlet.2010.02.018)